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Abstract
Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal
abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is
unknown. One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML
randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. By impact on survival, ACAs were grouped
into high risk (+8, +Ph, i(17q), +17, +19, +21, 3q26.2, 11q23, −7/7q abnormalities; complex) and low risk (all other). The
presence of high- and low-risk ACAs was linked to six cohorts with different blast levels (1%, 5%, 10%, 15%, 20%, and
30%) in a Cox model. One hundred and twenty-three patients displayed ACA/Ph+ (8.1%), 91 were high risk. At low blast
levels (1–15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in
marrow) in contrast to low-risk ACA. No effect was observed at blast levels of 20–30%. Sixty-three patients with high-risk
ACA (69%) died (n= 37) or were alive after progression or progression-related transplantation (n= 26). High-risk ACA at
low blast counts identify end-phase CML earlier than current diagnostic systems. Mortality was lower with earlier treatment.
Cytogenetic monitoring is indicated when signs of progression surface or response to therapy is unsatisfactory.
Introduction
Blast crisis (BC) of Philadelphia-chromosome-positive
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leukemia (CML) is one of the remaining challenges in the
management of the disease. Cytogenetic abnormalities and
blast increase represent the most consistent indicators of
progression to end-phase CML [1–7]. End-phase CML
comprises early progression with emerging high-risk ACA
and late progression with failing hematopoiesis and blast cell
proliferation. BC represents the end stage of this evolution.
Not all patients dying of CML reach the blast levels defining
BC (20% or 30% blasts in blood or marrow) [8–11]. Once
BC has occurred, treatment results are poor. Early allogeneic
stem cell transplantation (SCT) might improve prognosis
[12, 13]. Whether cytogenetic aberrations allow a timelier
change of treatment with better outcome is unknown.
Additional chromosomal abnormalities (ACAs) are
thought to result from BCR-ABL1-induced genetic
instability and may be causative factors of disease pro-
gression [14, 15]. The most frequent ACAs found in BC
(+8, a second Ph-chromosome (+Ph), an isochromosome
of the long arm of chromosome 17, i.e., i[17q], and +19)
were termed major route by Mitelman et al. [1–2]. Major-
route ACAs have been associated with shorter survival, if
they were detected at diagnosis [16] or if they emerged in
the course of disease [17]. A poor prognosis was also
observed with 3q26.2 and 11q23 rearrangements and with
−7/7q− [18, 19], whereas +8 and +Ph as single aberra-
tions, but not in combination, were not equally associated
with poor prognosis [20]. Wang et al. [17] proposed a risk
stratification of the six most frequent ACAs into two groups
with distinct prognoses (+8, +Ph, −Y with good prognoses
and i[17q], −7/7q−, 3q26.2 rearrangements with poor
prognoses). Using the same cohort of patients, a risk stra-
tification into three groups was proposed [21] based on BC
risk associated with each ACA (high risk: 3q26.2; −7/7q−;
i[17q]; complex karyotypes with high-risk ACA.
Intermediate 1: +8; +Ph; other single ACA. Intermediate 2:
other complex ACA).
Since the prognosis with single changes (+8, +Ph) is
controversial, we decided to include these in our evaluation,
as well as +21 and +17, which were designated as major
route later on [1]. Other ACAs were not so clearly asso-
ciated with shorter survival. This led to their tentative
designation as low-risk ACA.
More recently, clonal chromosomal aberrations (CCAs)
found in Ph-negative cells (CCA/Ph−) were reported to also
have a negative impact on survival [22, 23].
We here made use of the data of 1551 imatinib-treated
chronic phase (CP) patients recruited to CML-study IV, a
randomized study comparing imatinib 400 mg with
imatinib 800 mg and combinations of imatinib with inter-
feron, simultaneously or sequentially, or low-dose cytar-
abine [24]. Our aim was to analyze if defined ACA at low
blast levels allow an earlier diagnosis of end-phase CML




Patient data were derived from the randomized CML-study
IV (recruitment 2002–2012) with initial or predominant
imatinib treatment [24]. Documentation was done at 3–6-
month intervals as previously reported [24]. Risk assign-
ment followed the ELTS (EUTOS Long-Term Survival)
score [25]. BC was defined by 30% blasts in blood or
marrow. Patient numbers and flow are depicted in the flow
chart (Fig. 1a–c).
Fig. 1 Flow chart. a Patients
with ACA, b patients with BC,
and c transplanted patients with
high-risk ACA. BC blast crisis,
AP accelerated phase, SCT stem
cell transplantation.
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Cytogenetics
By protocol, cytogenetic analysis was requested every
3–6 months during the early disease phases and every
12 months thereafter, if stable molecular remission (major
molecular remission or better, BCR-ABL1 <0.1% on the
International Scale, IS) was achieved. In stable molecular
remission, intervals between cytogenetic analyses were
frequently longer due to patients’ and/or doctors’
requests. A median of four analyses per patient were
documented. Cytogenetic analyses were done as described
and results were reported according to the international
nomenclature (ISCN 2016) [16]. ACAs were evaluated if
they were clonal according to the ISCN. Complex kar-
yotypes were defined as three or more concurrent aber-
rations. High-risk ACAs were defined as the major route
ACA +8, +Ph, i[17q], +19, +21, +17 (the ACA most
frequently observed in BC) [1], the minor route ACA
3q26.2, 11q23, −7/7q− (less frequently observed, but
negative impact on prognosis) [17, 19, 18], and complex
karyotypes. Variant translocations and −Y were not
considered, as they had no impact on prognosis in our and
other studies [16, 26].
CAA/Ph− have not been an objective of this study.
Molecular genetics
Molecular analyses followed the IS methodology and
nomenclature [27–30].
Statistics
For survival analyses, patients were followed up at the
start of the diagnosis, at the time of the occurrence of an
ACA, or at the time of a blast increase. Patients were
censored at the date of last follow-up. Mortality after the
advent of blast increases was assessed by Cox models
starting at the time of a blast increase. Here the presence
of ACA was considered as a time-dependent covariate.
P values <5% were considered significant. Due to
the explorative character of this work, no adjustment of
p values was done and all p values have to be interpreted




One thousand five hundred and thirty-six patients with Ph+
CP-CML were analyzed for blast increase and ACA, 1510
patients were cytogenetically evaluable. Patients’
characteristics are shown in Table 1. Median observation
time was 8.6 years.
One hundred and twenty-three patients (8.1%) displayed
ACA in Ph+ metaphases (Appendix A1). Ninety one (6%)
were high-risk ACAs (+8, +Ph, i[17q], +17, +19, +21,
11q23 and 3q26.2 rearrangements, −7/7q abnormalities,
complex karyotypes) and 32 (2.1%) were low-risk ACAs
(all other). Of the 91 high-risk ACAs, 25 (1.7%) were
detected at baseline and 66 (4.4%) emerged in the course of
Table 1 Patient characteristics.
Patients (cytogenetically evaluable), n 1536 (1510)
Gender (%), male 60.2
Age at diagnosis of CML (years), median (range) 53 (16–88)
Hb (g/dl), median (range) 12.3 (4.7–19.1)
Platelets (×1012/μl), median (range) 375 (34–3020)
Patients with palpable splenomegaly 55.7%
ELTS-score (% low/intermediate/high) 57/30/13
WBC count at diagnosis (×109/l) (median, range)
with differential
76 (2.6–630)
Blasts (%) 1 (0–30)
Promyelocytes (%) 2 (0–34)
Basophils (%) 3 (0–66)
Median observation time (years) 8.6
10-Year survival 83%
Patients with ACA, high risk at diagnosis (n) 25
Patients with ACA, high risk in the course of
disease (n)
66
High-risk ACA total (n) 91 (6%)
Patients with other-/low-risk ACA at diagnosis (n) 19
Patients with other-/low-risk ACA in the course of
disease (n)
13
Low-risk ACA, total (n) 32 (2.1%)
ACA total (n) 123 (8.1%)
Patients with anemia (Hb < 10) at first appearance
of ACA (%)
26.7a
Patients with thrombocytopenia (platelets < 75 ×
109/l) at first appearance of ACA (%)
17.8a
Patients with neutropenia (neutrophils < 1.5 × 106/l)
at first appearance of ACA (%)
15.5a
Patients with palpable splenomegaly (defined as
spleen in cm below costal margin >0) at first
appearance of ACA (%)
39.2a
Basophils at the time of ACA (%) (median, range) 1 (0–15)a
Age at diagnosis of ACA (years) (median, range) 52 (18–89)
Age at diagnosis of high-risk ACA (years)
(median, range)
52 (23–89)
Median interval diagnosis—ACA (years) (median,
range)
n.r. (0–11.1)b
aOnly values up to 4 weeks in advance or 1 week after the first
appearance of ACAs were counted (n ≥ 74).
bMaximum number = emergence of last ACA, n.r. not reported.
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disease 0.5–133 months after diagnosis. The median time to
detection of high-risk ACAs was 17 months. Of the 32 low-
risk ACAs, 19 (1.3%) were detected at diagnosis and 13
(0.9%) emerged in the course of disease.
Frequencies of ACA are shown in Table 2 grouped
according to type (risk level, single, or in combination) and
time of emergence (at diagnosis or in the course of disease).
Impact of ACA on survival
Figure 2a–d shows the impact of high- and low-risk ACAs
on survival from occurrence of ACA at diagnosis or in the
course of disease. Observations were synchronized for the
time of emergence of ACA, and ACA detected at diagnosis
and emerging in the course of disease were analyzed
together. All high-risk ACAs show a negative impact on
survival compared to low-risk ACAs, which serve as con-
trol. An exception is +8 as a single aberration, which car-
ries a prognosis in between high- and low-risk ACAs
(Fig. 2a). Impact of +Ph on survival was equally poor
whether it occurred alone or in combination with other
abnormalities (Fig. 2b). Chromosome 3, 7, 17, 19, and 21
aberrations were grouped together, as they were rare
(Fig. 2d). Individual analyses of these aberrations are shown
in Fig. 2e–i. Four-year survival probability after occurrence
of high-risk ACA, except +8 alone, was 52.2% (95%
confidence interval (CI): 41–66), after occurrence of +8
alone 77% (95% CI: 60–100), and after occurrence of low-
risk ACA 87% (95% CI: 75–100).
The treatment strategy after emergence of ACA includ-
ing allogeneic SCT did not differ according to the type of
ACA, but patients with high-risk ACA were transplanted
more frequently. 42 of the 138 transplantations in CML-
study IV (30%) were performed in the 6% of patients with
high-risk ACA (Flow chart, Fig. 1c). Two-year survival of
26 patients transplanted in BC or accelerated phase (AP)
was 46% (95% CI: 26–63%) and of 13 patients transplanted
in CP 77% (95% CI: 44–92%; log-rank test: p= 0.09; phase
unknown for 3 of 42 patients).
Correlation of ACA with BC
79 patients developed BC during the observation time. Of
the 79 BC patients, 71 were cytogenetically evaluable. 44
BC patients had ACA (61%), in 27 patients no ACAs were
reported. Of the 44 BC patients with ACA, 41 (93%) had
high-risk and 3 low-risk ACA (Flow chart, Fig. 1b).
Correlation of ACA with blast increase
The close correlation of high-risk ACA with BC and the
unfavorable prognosis of patients with high-risk ACA led
us to ask if high-risk ACA can anticipate the diagnosis of
end-phase CML. We therefore assigned patients, in whom a
blast increase was observed in peripheral blood or marrow
(at any time), to 6 different blast thresholds (1%, 5%, 10%,
15%, 20%, and 30%). In each of these cohorts high- and
low-risk ACAs were considered as time-dependent vari-
ables. The number of patients ranged from 224 to 78 in the
six cohorts with blast increases of 1% to >30% in the per-
ipheral blood, and from 1033 to 79 in the six cohorts with
Table 2 Frequency of ACA.
Karyotypes Single ACA In combination with
other ACA
Total
High-risk ACA (n= 91)a
+8 19 19 38
At diagnosis 6 10 16
In the course of
disease
13 9 22
+Ph 18 17 35
At diagnosis 7 6 13
In the course of
disease
11 11 22
+19 0 11 11
At diagnosis 0 4 4
In the course of
disease
0 7 7
+17/i(17q) 3 5 8
At diagnosis 1 3 4
In the course of
disease
2 2 4
3q26.2 10 2 12
At diagnosis 1 0 1
In the course of
disease
9 2 9
−7/7q abnormalities 5 4 9
At diagnosis 1 0 1
In the course of
disease
4 4 8
+21 2 3 5
At diagnosis 1 1 2
In the course of
disease
1 2 3
11q23 1 0 1
At diagnosis 0 0 0
In the course of
disease
1 0 1
Complex karyotypes 25 25
At diagnosis 11 11
In the course of
disease
14 14
Low-risk ACA 32 32
At diagnosis 19 19
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blast levels of 1% to >30% in the marrow (Table 3).
Naturally, the sets of patients who developed higher blast
increases later on were subsets of the sets with lower blast
increases.
In the corresponding Cox proportional hazards models
(Table 3, Fig. 3), we found an increased hazard to die in the
presence of high-risk ACA compared to no ACA with
hazard ratios of up to 3.65 (95% CI: 2.32–5.75) in the blood
(Fig. 3a) and 6.12 (95% CI: 4.1–9.2) in the marrow
(Fig. 3b) when only patients with low blast levels of 1–5%
were considered. When restricting the cohorts to larger blast
increases, the effect of high-risk ACA on the hazard to die
decreased. In the last cohorts of patients with blast increases
to at least 20% or 30%, no difference between patients with
and without high-risk ACA was found (hazard ratio: 0.83,
95% CI: 0.50–2.89). The hazard ratios for low-risk ACA
compared to no ACA were increased to much lesser extents
than for high-risk ACA.
Fig. 2 Impact of high- vs. low-risk ACA on survival. The left-side
panel shows the impact of +8 (a), +Ph (b), complex ACA (c), and of
chromosome 3, 7, 17, 19, and 21 aberrations combined (d) on survival
in patients with primary imatinib treatment after the emergence of
ACA. Suvival after emergence of low-risk ACA in imatinib-treated
patients serves as control. The right-side panel shows the impact of
rare high-risk ACA of chromosomes 3, 7, 17, 19, and 21 on survival
(e–i).
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Course of disease and causes of death
Thirty-seven patients with high-risk ACA (41%) died (Flow
chart, Fig. 1a, c). The causes of death were known for 34
patients and almost exclusively CML related. Thirty-two
patients (94%) died of progression, mostly in BC, including
21 after progression-related transplantation (15 in BC, 1 in
AP, 2 after loss of cytogenetic remission, 2 because of no
molecular response, and 1 with unknown indication). Two
patients died of CML-unrelated causes.
Of 54 (59%) living patients with high-risk ACAs, 21
(23% of total) were transplanted, 8 of these in BC, 2 in AP,
9 because of no molecular response, and 2 with unknown
indication. Five (5%) non-transplanted patients are alive
after progression (Flow chart, Fig. 1a, c). Twenty-eight
patients (31%) are alive without documented progression
0–11 years after emergence of high-risk ACA.
Of the four patients with low-risk ACA who died, three
died of CML-related (one after SCT) and one of CML-
unrelated causes
Table 3 Hazard to die in IM-
treated patients with high- and
low-risk ACA dependent on
blast increase to 1–30% (Cox
model).
HR Lower 95% CI Upper 95% CI P value n
Peripheral blood (PB)
1% blasts in PB
Presence of high-risk ACAs 3.65 2.32 5.75 <0.001 224
Presence of low-risk ACAs 1.92 1.06 8.07 0.039
5% blasts in PB
Presence of high-risk ACAs 1.11 2.86 0.016 117
Presence of low-risk ACAs 1.77 0.68 4.66 0.244
10% blasts in PB
Presence of high-risk ACAs 1.39 0.87 2.21 0.167 107
Presence of low-risk ACAs 1.38 0.53 3.60 0.506
15% blasts in PB
Presence of high-risk ACAs 1.37 0.86 2.19 0.189 104
Presence of low-risk ACAs 1.32 0.51 3.42 0.568
20% blasts in PB
Presence of high-risk ACAs 0.84 0.50 1.40 0.502 79
Presence of low-risk ACAs 0.74 0.20 2.71 0.652
30% blasts in PB
Presence of high-risk ACAs 0.83 0.50 1.39 0.479 78
Presence of low-risk ACAs 0.76 0.20 2.89 0.689
Bone marrow (BM)
1% blasts in BM
Presence of high-risk ACAs 6.12 4.08 9.17 <0.001 1033
Presence of low-risk ACAs 2.71 0.99 7.44 0.053
5% blasts in BM
Presence of high-risk ACAs 5.46 3.58 8.33 <0.001 588
Presence of low-risk ACAs 3.21 1.16 8.85 0.024
10% blasts in BM
Presence of high-risk ACAs 2.21 1.37 3.56 0.001 134
Presence of low-risk ACAs 1.68 0.61 4.60 0.311
15% blasts in BM
Presence of high-risk ACAs 1.77 1.11 2.83 0.017 115
Presence of low-risk ACAs 1.66 0.63 4.37 0.309
20% blasts in BM
Presence of high-risk ACAs 1.24 0.74 2.06 0.416 87
Presence of low-risk ACAs 1.11 0.29 4.18 0.882
30% blasts in BM
Presence of high-risk ACAs 0.89 0.53 1.49 0.665 79
Presence of low-risk ACAs 0.81 0.21 3.07 0.760
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Discussion
We here report that the combination of high-risk ACA and
low-level blasts heralds progression and death by CML.
This finding has implications for diagnosis and management
of patients in end-phase CML. High-risk ACAs allow to
identify CML end-phase at an earlier time than is possible
with the current blast thresholds [9, 10]. These patients
require a change of therapy and/or more intensive treat-
ments, for example, with ponatinib or allogeneic SCT [9]. A
clinically relevant, but in 39 patients not statistically sig-
nificant difference of 30% 2-year survival suggests that
outcome of transplanted patients with high-risk ACA
depends on disease stage similar to patients without ACA
[12]. Successful treatment may explain, at least in part, the
plateau phase of survival curves after 4 years.
High-risk ACA at low blast counts are not an indicator of
AP as previously reviewed [31, 32], but a marker of pro-
gression and death by CML regardless whether they are
present at diagnosis or emerge in the course of disease.
Sixty-nine percent of patients with high-risk ACA and low
blast levels progressed or died of CML during the obser-
vation period. This includes transplanted patients who as a
rule were transplanted because of progression. Our findings
agree with an earlier observation that patients in AP with
ACA and blast increase have a worse outcome [33].
Our data suggest that the appropriate time for a change of
treatment is emergence of high-risk ACA rather than wait-
ing for an increase of blasts.
High-risk ACA include, in addition to major route ACA
(which were defined solely on the basis of their frequency in
BC) [1–2], most notably −7/7q−, 3q26.2, and 11q23
rearrangements and complex karyotypes [16–21, 26].
Additional high-risk ACA may surface on continued clin-
ical and cytogenetic scrutiny.
Our definition of high-risk ACA largely agrees with that
proposed by others [17, 21], but there are differences. The
prognosis with +8 alone, although clearly better than with
+8 in combination, is still worse than with low-risk ACA
(Fig. 2a). We thus have included +8 alone in the high-risk
ACA group. +Ph has an equally unfavorable impact on
survival, regardless whether it occurs as a single aberration
or in combination (Fig. 2b). In agreement with earlier
reports [17, 18], chromosome 19 aberrations exclusively
occurred in combination, whereas 3q26.2 was mostly found
as a single aberration and rarely at diagnosis [16]. −Y in our
analyses had a prognosis not different from no ACA.
Looking at our data in context of the literature [17, 21], a
risk stratification of ACA in two risk-groups (high risk with
impact on survival and low risk with little or no impact)
seems useful for clinical purposes. Due to the limited
sample size and the exploratory nature of this work, we
would welcome verification of these results by others.
High-risk ACAs were not observed in all BC patients.
We cannot rule out that other events such as genetic
alterations not detectable by cytogenetics predispose to a
blast increase. Gene sequencing detects such alterations
[34]. Telomere shortening [35] or increased separase
activity [36] may contribute to progression. Likewise, low-
risk ACA might include some hitherto unrecognized high-
risk ACA as suggested by the three patients with BC and
low-risk ACA.
High-risk ACAs were observed in 6% of CP patients, but
in 61% of patients who had progressed to BC, whereas low-
risk ACAs were observed in 2.1% of CP patients and in
Fig. 3 Hazard to die with high-risk and low-risk ACA compared to
no ACA dependent on blast counts. Hazard ratios for mortality in
imatinib-treated patients with high-risk and low-risk ACA were
determined in six different (but overlapping) patient groups (blast
increase to 1–30%) together with 95% confidence intervals a in per-
ipheral blood and b in bone marrow. The size of the circle correlates
with the sample size. Thirty-seven patients with high-risk ACA and
four patients with low-risk ACA died. In 34 patients with high-risk
ACA, causes of death were known. Thirty-two of these (94%) died of
progression, including progression-related transplantation in 21
patients. Two patients died of CML-unrelated causes. Causes of death
were unknown in three patients. With low-risk ACA, causes of death
were CML related in three patients and unknown in one patient.
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2.8% of patients with BC. This is strong support for a role
of high-risk ACA in the evolution of CML and is in line
with the hypothesis that BCR-ABL1 predisposes to ACA,
which then promote progression. The emergence of high-
risk ACA might anticipate and define the point of no return
in the evolution of CML indicating non-reversibility by
tyrosine kinase inhibitor (TKI). High-risk ACA could
emerge as testable cause of non-mutation-related TKI
resistance.
A limitation of this study is the follow-up cytogenetics,
which have been replaced in many instances by molecular
testing increasingly done in the course of the study. Fur-
thermore, most cytogenetic analyses were performed in the
first months after diagnosis or when the patients’ conditions
were worsening. This might introduce a bias, as patients
doing well were usually not analyzed. Also, it is possible
that analyses with low numbers of mitoses miss ACA and
that the true percentage of patients with ACA is
underestimated.
Although the low number of follow-up cytogenetics has
limited the direct correlation of ACA with blast increase, it
points to the strength of the evidence for the association of
high-risk ACA with end-phase CML and survival in the
Cox model in spite of missing values.
A correlation with BCR-ABL1 transcript numbers was
not conclusive because of too few molecular measurements
at early blast increase.
A strength of the study is the size of the cohort as one of
the largest of TKI-treated CP-CML patients on whom
emergence of ACA and progression to BC were pro-
spectively recorded in parallel over prolonged periods of
time. The association of high-risk ACA with progression
would not be so obvious in smaller cohorts with shorter
observation.
In conclusion, high-risk ACAs are an early marker of
CML progression. In the presence of low blast levels, high-
risk ACAs indicate death by CML earlier than is possible
with standard blast thresholds. An appropriate time for a
change of therapy may be emergence of high-risk ACA
rather than waiting for an increase of blasts. Cytogenetic
monitoring is indicated when signs of progression surface
and response to therapy is unsatisfactory.
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Appendix A1. Karyotypes of patients with
ACA
No. Sex Agea Intervalb Karyotype
High-risk ACA in Ph+ cells
1 F 54 11 46,XX,inv(3)(q21q26),t(7;9;22)(q31;q34;q11) [20]
16 46,XX,inv(3)(q21q26),t(7;9;22)(q31;q34;q11) [25]
20 46,XX,inv(3)(q21q26),t(7;9;22)(q31;q34;q11) [25]
2 F 45 28 46,XX,inv(3)(q21q26),t(9;22)(q34;q11) [19]
32 46,XX,inv(3)(q21q26),t(9;22)(q34;q11) [2]









4 M 42 0 46,XY,inv(3)(p13q25),t(9;22)(q34;q11) [17]
5 F 32 12 46,XX,inv(3)(q21q26),t(9;22)(q34;q11) [15]
6 M 43 8 46,XY,inv(3)(q21q26),t(9;22)(q34;q11) [24]
7 F 37 6 46,XX,t(3;21)(q26;q22),t(9;22)(q34;q11) [15]
7 46,XX,t(3;21)(q26;q22),t(9;22)(q34;q11) [17]
8 46,XX,t(3;21)(q26;q22),t(9;22)(q34;q11) [20]









9 M 60 6 48–49,XY,t(5;9)(q31;q22),−7,der(7)del(7)(p11)del(7)(q11),+8,
der(9)t(7;9)(q11;p23)t(9;22)(q34;q11),+19,der(22)t(9;22)(q34;
q11),+der(22)t(9;22)[cp12]




11 M 45 13 46,XY,r(7)(p11q32)del(7)(q11q22),del(9)(p12p24),t(9;22)(q34;
q11) [6]
12 M 36 25 43–44,XY,−8,t(9;22)(q34;q11),−11,−15,−17,−18,−19,−20,
−22,+2–3mar[cp10]













16 F 54 45 46,XX,t(3;21)(q26;q22),t(9;22)(q34;q11) [25]
48 46,XX,t(3;21)(q26;q22),t(9;22)(q34;q11) [25]








19 M 61 0 46,XY,t(9;22)(q34;q11) [14]/46,XY,der(9)t(9;22)(q34;q11),ider
(22)(q10)t(9;22)(q34;q11) [11]
20 M 51 44 47,XY,t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11) [4]
21 M 61 46 46,XY,t(9;22)(q34;q11),+der(22)idic(9)(q34)t(9;22)(q34;q11),
+der(22)t(9;22)(q34;q11)x3,+mar[cp20]
64 49,XY,t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11)x3 [3]
22 F 60 2 46,XX,der(7)t(7;22)(q36;q11)del(7)(q11q22),der(9)t(7;9)(q36;
q34),der(22)t(9;22)(q34;q11) [21]
23 M 46 0 47,XY,der(9)t(9;22)(q34;q11),del(9)(q33q34),del(22)(q11q12),
+der(22)t(9;22)(q34;q11) [25]
24 F 59 6 46,XX,der(9)t(9;22;15)(q34;q11;q26),der(15)t(9;22;15),+22,der
(22)idic(22)(p11)t(9;22) [15]
25 M 34 3 48,XY,+X,der(5)t(1;5)(q21;q31),t(9;22;21)(q34;q11;q22),+der
(22)t(9;22) [15]




27 M 36 72 46,XY,t(9;22)(q34;q11)/47,XY,t(9;22)(q34;q11),+der(22)t(9;22)
(q34;q11) [3]
28 M 54 9 47,XY,t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11) [6]




30 M 32 18 47,XY,t(1;14)(p3?1;q?32),del(9)(p22p24),t(9;22)(q34;q11),+der
(22)t(9;22)(q34;q11) [9]/
46,XY,del(9)(p22p24),t(9;22)(q34;q11),del(12)(p11.2p13) [6]
31 M 78 13 45,X,−Y,del(9)(q22),+der(22)t(9;22)(q34;q11)t(9;9)(q34;q22)
[13]
32 M 38 27 47,XY,t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11) [14]
33 M 23 0 46,XY,t(9;22)(q34;q11) [18]/47,idem,+der(22)t(9;22)(q34;q11)
[2]
34 M 68 19 46,XX,t(9;22)(q34;q11) [5]/48,XX,t(9;22)(q34;q11),+19,+der(22)
t(9;22)(q34;q11) [8]




36 M 51 27 46,XY,t(9;22)(q34;q11) [14]/48,idem,+19,+der(22)t(9;22)(q34;
q11) [2]
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38 M 39 12 46,XY,t(9;22)(q34;q11) [7]/47,XY,+8,t(9;22)(q34;q11) [2]/48,
XY,+8,t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11) [3]
88 46,XY,t(9;22)(q34;q11) /47,XY,+8,t(9;22)(q34;q11) /48,XY,+8,
t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11) [16]
39 F 58 7 55,XX,+X,+5,+6,+7,+8,t(9;22)(q34;q11),+14,+19,+22,+der
(22)t(9;22)(q34;q11)[cp5]
40 M 38 15 47,XY,t(9;22)(q34;q11),+8 [2]
41 M 39 0 47,XY,+8,t(9;22)(q34;q11) [2]/47,XY,+8,t(9;22)(q34;q11),i(17)
(q10) [2]/48,XY,+8,t(9;22)(q34;q11),i(17)(q10),+22,
del(22)q11) [10]
42 M 64 10 46,XY,t(9;22)(q34;q11) [16]/50,XY,+8,+12,+18,+21,t(9;22)
(q34;q11) [3]
43 M 34 5 46,XY,t(9;22)(q34;q11) [13]/47,XY,+8,t(9;22)(q34;q11) [5]
117 46,XY,t(9;22)(q34;q11) [9]/47,XY,+8,t(9;22)(q34;q11) [6]
44 F 54 73 46,XX,t(9;22)(q34;q11) [2]/47,XX,+8,t(9;22)(q34;q11) [12]
81 47,XX,+der(8),t(1;8)(q22;p22),t(9;22)(q34;q11) [2]
45 F 42 51 46,XX,t(9;22)(q34;q11) [17]/47,XX,+8,t(9;22)(q34;q11) [3]
46 M 72 0 47,XY,+8,t(9;22)(q34;q11) [20]
7 46,XY,t(9;22)(q34;q11) [6]/47,XY,+8,t(9;22)(q34;q11) [18]
47 M 40 0 47,XY,+8,t(9;22)(q34;q11) [17]/49,XY,+8,t(9;22)(q34;q11),+19,
+20 [7]
48 M 25 0 46,XY,t(9;22)(q34;q11) [22]/47,XY,+8,t(9;22)(q34;q11) [3]
49 F 24 23 46,XX,t(9;22)(q34;q11) [4]/47,XX,+8,t(9;22)(q34;q11) [4]
29 46,XX,t(9;22)(q34;q11) [11]/47,XX,+8,t(9;22)(q34;q11) [2]
36 46,XX,t(9;22)(q34;q11) [3]/47,XX,+8,t(9;22)(q34;q11) [18]
40 47,XX,+8,t(9;22)(q34;q11) [20]
44 47,XX,+8,t(9;22)(q34;q11) [5]
50 M 31 0 46,XY,t(9;22;10)(q34;q11;p15) [13]/55,XY,+3,+8,t(9;22;10)
(q34;q11;p15),+12,+13,+14,+18,+19,+21,+der(22)
t(9;22(q34;q11) [7]








53 F 68 0 48,XX,+8,t(9;18)(q34;q21),+der(22)ins(22;9)(q11;34q34) [5]
6 48,XX,+8,t(9;18)(q34;q21),+der(22)ins(22;9)(q11;34q34) [4]
54 M 38 0 47,XY,+8,t(9;22)(q34;q11) [3]/48,XY,+8,t(9;22)(q34;q11),+der
(22)t(9;22)(q34;q11) [11]
55 M 53 0 50,XY,+8,+8,i(17)(q10),+19,+der(22)t(9;22)(q34;q11) [6]
56 M 28 10 45,XY,t(8;21)(q22;q22),t(9;22)(q34;q11),−11/93,XXYY,+8,+8,t
(8;21)(q22;q22),t(9;22)(q34;q11),−11 [8]
57 M 70 19 46,XY,t(9;22)(q34;q11) [19]/47,XY,+8,t(9;22)(q34;q11) [4]
64 46,XY,t(9;22)(q34;q11) [4]/47,XY,+8,t(9;22)(q34;q11) [16]
58 M 55 0 46,XY,t(1;12)(p34;q24),t(1;9;22)(p36;q34;q11) [21]/48,idem,+8,
+9 [2]
59 M 46 52 46,XY,t(9;22)(q34;q11) [8]/47,XY,+8,t(9;22)(q34;q11) [7]
72 46,XY,t(9;22)(q34;q11) [19]/47,XY,+8,t(9;22)(q34;q11) [4]
80 47,XY,+8,t(9;22)(q34;q11) [4]
86 46,XY,t(9;22)(q34;q11) [4]/47,XY,+8,t(9;22)(q34;q11) [13]
60 M 64 42 46,XY,t(9;22)(q34;q11) [17]/47,XY,+8,t(9;22)(q34;q11) [2]
53 46,XY,t(9;22)(q34;q11) [17]/47,XY,+8,t(9;22)(q34;q11) [2]
57 46,XY,t(9;22)(q34;q11) [5]/47,XY,+8,t(9;22)(q34;q11) [2]
65 46,XY,t(9;22)(q34;q11) [4]/47,XY,+8,t(9;22)(q34;q11) [2]
69 47,XY,+8,t(9;22)(q34;q11) [2]/46,XY,del(7)(q11;q22) [6]
61 M 57 0 48,XY,+8,t(9;22)(q34;q11),+19 [25]
62 M 50 76 46,XY,t(9;22)(q34;q11)/47,XY,+8,t(9;22)(q34;q11),idic(17)(p11)
[24]
63 M 46 102 47,XY,+8,t(9;22)(q34;q11),i(17)(q10) [6]
64 M 41 0 46,XY,t(9;22)(q34;q11) [10]/44,XY,t(9;22)(q34;q11),−14,i(17)
(q10),−18 [15]
65 F 62 10 46,XX,t(1;9;22)(p36;q34;q11) [8]/47,XX,t(1;9;22)(p36;q34;q11),
+8 [2]
66 F 76 8 47,XX,+8,t(9;22)(q34;q11) [3]
67 M 44 20 46,XY,t(3;21)(q26;q22),t(9;22)(q34;q11) [16]/46,XY [4]
No. Sex Agea Intervalb Karyotype
34 49,XY,t(3;21)(q26;q22),+8,t(9;22)(q34;q11),+12,+der(22)t(9;22)
(q34;q11) [4]/46,XY [19]
68 F 52 0 47,XX,+8,t(9;22)(q34;q11),i(17)(q10) [10]
3 47,XX,+8,t(9;22)(q34;q11),idic(17)(p12) [4]/46,XX [21]
8 50,XX,+8,+8,+8,t(9;22)(q34;q11),idic(17)(p12),+19 [7]/46,XX
[20]
69 F 56 0 46,XX,t(9;22)(q34;q11) [21]/47,XX,+8,t(9;22)(q34;q11) [2]
70 M 48 0 46,XY,t(9;22)(q34;q11) [6]/47,XY,+8,t(9;22)(q34;q11) [12]
71 M 51 0 46,XY,t(9;22)((q34;q11) [7]/47,XY,+8,t(9;22)(q34;q11),i(17)
(q10) [18]
72 F 75 24 47,XX,t(9;22)(q34;q11),+21 [4]
73 F 39 0 46,XX,t(9;22)(q34;q11) [3]/46,idem,t(20;21)(q10;q10) /47,idem,t
(20;21)(q10;q10),+21 [11]
74 M 42 19 47,XY,t(9;22)(q34;q11),+17 [20]
21 47,XY,t(9;22)(q34;q11),+17 [10]
75 F 62 11 46,XX,t(9;11)(p21–22;q23),t(9;22)(q34;q11) [25]
76 M 51 38 46,XY,t(9;22)(q34;q11),inv(16)(p13q22),+der(22)t(9;22)(q34;
q11) [3]
77 F 59 32 48,XX,t(9;15;22) (q34;q26;q11),+8,+19 [3]
78 F 51 7 45,XX,der(7;9)(q10;q10)t(9;22)(q34;q11) [8]
79 M 24 8 46,XY,der(9)t(9;22)(q34;q11),der(19)t(9;19)(q34;p13);der(22)t
(9;22)(q34;q11)
t(9;19)(q34,p13) [2]
80 M 53 0 46,XY,der(9)t(9;22)(q34;q11),idicder(22)(q11)t(9;22)(q34;q11),
idicder(22)(q11)t(9;22)(q34;q11) [3]
81 M 55 0 46,XY,der(7)t(7;9)(q11.2;q34),der(9)t(9;22)(q34;q11.2),der(22)t
(9;22)(q34;q11.2)
t(7;9)(q11.2q34) [13]
82 M 40 0 47,XY,+8,t(9;22)(q34;q11) [16]
83 F 68 13 46,XX,t(3;11)(q26;q23),t(9;22)(q34;q11) [20]
84 F 54 45 46,XX,t(3;21)(q26;q22),t (9;22)(q34;q11) [25]




86 M 60 22 46,XY,inv(7)(p22q32),+8,t(9;22)(q34;q11) [20]












88 F 38 0 46,XX,del(1)(q21),der(9)t(9;22)(q34;q11)t(1;22)(q44;q11),der(22)
t(9;22)(q34;q11)t(1;9)(q21;q34) [20]
89 F 66 0 46,XX,del(1)(q32),der(9)t(1;9)(q32;q34)t(1;22)(q44;q11),der(22)t
(9;22)(q34;q11) [20]
90 M 55 0 46,XY,t(7;11),del(7q),der(9)t(9;22)(q34;q11),der(11),del(16q),der
(17),der(22)t(9;22)(q34;q11) [10]
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93 M 48 0 46,XY,t(4;6)(q21;p23),t(9;22)(q34;q11) [20]
94 M 36 12 46,XY,t(9;22)(q34;q11) [8]/46,XY,t(9;22)(q34;q11),i(9)(p10),der
(17)t(9;17)(q11;p11) [12]
95 F 58 0 46,XX,t(9;22)(q34;q11) [6]/92,XXXX,t(9;22)(q34;q11)x2 [4]
96 M 44 0 46,XY,der(10),t(9;22)(q34;q11) [25]
97 M 46 0 46,XY,t(9;22)(q34;q11),t(14;17)(p11;q11) [20]
98 M 40 0 46,XY,t(9;22)(q34;q11) [2]/46,XY,del(5)(q11q14),t(9;22)(q34;
q11) [19]
6 46,XY,del(5)(q11q14),t(9;22)(q34;q11) [2]
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
No. Sex Agea Intervalb Karyotype
99 F 51 7 46,XX,t(9;22)(q34;q11) [4]/45,XX,der(7;9)(q10;q10)t(9;22)(q34;
q11),der(22)t(9;22)(q34;q11) [8]
100 M 27 0 46,XY,t(9;22)(q34;q11) [20]/45,XY,t(9;22)(q34;q11),−21 [4]
101 F 52 0 46,XX,t(2;16)(p2?3;p1?3),t(9;22)(q34;q11) [26]
102 F 61 0 46,XX,t(9;22)(q34;q11) [21]/46,XX,del(6)(q15q23),t(9;22)(q34;
q11) [4]
103 F 68 0 46,XX,t(9;22)(q34;q11) /46,XX,del(5)(q13q22),t(9;22)(q34;q11)
[24]
104 F 64 0 46,XX,t(5;8)(q14;q23),t(9;22)(q34;q11) [19]
105 M 37 0 46,XY,t(9;22)(q34;q11),t(15;20)(q13;p12) [20]
106 F 45 39 46,XX,t(9;22)(q34;q11.2) [16]/46,XX,t(9;22)(q34;q11.2),add(20)
(p11.2) [9]
107 M 19 0 46,XY,der(1)t(1;9)(q21;q34)t(9;22)(q34:q11),der(9)t(1;9)(q21;
q34)t(9;22)(q34:q11),der(22)t(9;22)(q34;q11) [3]
108 F 65 86 46,XX,t(9;22)(q34;q11) [17]/46,XX,del(X)(p?21),t(9;22)(q34;q11)
[6]
109 M 64 10 46,XY,add(9)(q34),add(9)(q32–34),der(22)t(9;22)(q34;q11) [10]
14 46,XY,t(1;3)(p36;q2?6),add(9)(q34),add(9)(q32–34),der(22)t
(9;22)(q34;q11) [10]
110 F 56 0 46,XX,t(1;21)(q21;q22),t(9;22)(q34;q11) [20]
12 46,XX,t(1;21)(q21;q22),t(9;22)(q34;q11) [15]
24 46,XX,t(1;21)(q21;q22),t(9;22)(q34;q11) [2]
111 M 36 0 46,XY,t(9;22)(q34;q11),t(11;19)(q14.1;q13) [20]
112 M 62 0 46,XY,t(9;22)(q34;q11) [2]/46,idem,add(8)(q24) [2]/45,idem,der
(18)t(10;18)(q11;p11) [10]
113 M 61 0 46,XY,t(1;9)(q24;q31),t(9;22)(q34;q11) [20]
114 F 46 0 46,XX,der(2)t(2;4)(q37;q21)del(4)(q21),t(9;22)(q34;q11) [20]
115 M 70 0 46,XY,der(9)t(9;22)(q34;q11),t(10;22)(q25;q13) [17]
4 46,XY,der(9)t(9;22)(q34;q11),t(10;22)(q25;q13) [3]
7 45,X,−Y [3]/46,XY,der(9)t(9;22)(q34;q11),t(10;22)(q25;q13) [2]
116 F 69 94 46,XX,t(9;22)(q34;q11),?del(17)(p12) [4]
117 F 49 0 46,XX,del(3)(p11p2?1)or(p21),t(9;22)(q34;q11) [12]/46,XX,del(3)
(p11p2?1)or(p21),del(5)(q15q31),t(9;22)(q34;q11) /46,XX,t(9;22)
(q34;q11) [2]




119 M 40 3 46,XY,t(6;15),t(9;22)(q34;q11) [6]
120 M 66 11 46,XY,t(9;22)(q34;q11) [9]/46,XY,der(6)t(6;17)(p21;q11),t(9;22)
(q34;q11) [11]
121 F 43 0 46,XX,t(7;7)(p22;q22),t(9;22;9)(q34;q11;p24) [16]
60 40–43,XX,t(7;7)(p22;q22),t(9;22;9)(q34;q11;p24),inc [cp3]
122 M 24 6 46,XY,t(2;12)(q33;p13),t(9;22)(q34;q11) [20]
123 F 31 11 46,XX,t(9;22)(q34;q11) [18]/ 46,XX,t(9;22)(q34;q11),ins(11;11)
(p15;p11.2p13) [4]
25 46,XX,t(9;22)(q34;q11) [9]/ 46,XX,t(9;22)(q34;q11),ins(11;11)
(p15;p11.2p13) [5]
aAge at diagnosis (years).
bInterval between diagnosis and emergence of ACA (months).
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